🇺🇸 FDA
Patent

US 8470888

Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer

granted A61KA61K31/165A61K31/277

Quick answer

US patent 8470888 (Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/165, A61K31/277, A61K31/353, A61P